05
059210.KQ Meta Biomed Co. Ltd
- Market cap
- KRW 96.1B
- P/E
- -
- P/B
- 0.74x
- ROE
- 16.7%
- Dividend yield
- 0.71%
- Fundamental score
- 3.2/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 059210.KQ undervalued?
Graham numberThe Graham number of Meta Biomed Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Meta Biomed Co. Ltd fundamental analysis
14 of 22 checks passedROE 1/2
Moderate return on equity (16.7%), between 10% and 20%.
ROA 1/1
Return on assets (11.2%) is above the industry median (6.2%).
Profit Consistency 2/2
Profitable for 5 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-58.2%) is below the industry median (0.5%).
Revenue Growth 2/2
Revenue grew 14.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (4.4%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 15.5x against interest expense, well covered.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (0.7x) is above the industry median (0.7x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield (0.7%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 11 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 6.2%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Meta Biomed Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Meta Biomed Co. Ltd
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone products consisting of bone graft substitutes and cement; and cosmetic medical products…
Full company profileMeta Biomed Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Meta Biomed Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 65.8B | 65.3B | 52.6B | 59.4B | 47.2B | 58.8B | 68.9B | 83.1B | 94.0B | 103B | 103B |
| Gross Profit | 23.8B | 20.7B | 19.2B | 26.1B | 20.1B | 25.0B | 29.2B | 38.0B | 47.4B | 53.6B | 56.8B |
| Operating Income | 3.60B | -1.23B | -537M | 5.74B | -2.66B | 4.40B | 4.88B | 9.73B | 17.2B | 21.4B | 22.3B |
| EBITDA | - | - | - | - | - | - | 8.16B | 14.3B | 32.0B | 20.9B | 35.8B |
| Net Income | 639M | -4.10B | -1.15B | 3.35B | -4.09B | 9.52B | 2.63B | 10.1B | 22.4B | 11.0B | 21.7B |
| EPS | 30 | -191 | -49 | 144 | -179 | 416 | 115 | 441 | 981 | 410 | 799 |
| Balance Sheet | |||||||||||
| Total Assets | 120B | 120B | 97.7B | 103B | 108B | 103B | 121B | 130B | 177B | 187B | 195B |
| Total Liabilities | 68.5B | 73.7B | 47.7B | 50.0B | 59.9B | 44.8B | 60.5B | 57.5B | 84.0B | 61.7B | 64.2B |
| Shareholders' Equity | 51.6B | 46.0B | 50.0B | 53.3B | 48.0B | 58.3B | 60.6B | 70.0B | 93.3B | 124B | 130B |
| Cash & Short-term Investments | 8.62B | 6.06B | 11.2B | 8.10B | 21.0B | 15.9B | 19.1B | 16.8B | 54.3B | 18.0B | 15.3B |
| Total Debt | 50.4B | 58.1B | 34.8B | 38.1B | 48.6B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 5.03B | -249M | -5.28B | 2.86B | 4.86B | 11.1B | 9.16B | 10.2B | 22.6B | 19.8B | 12.6B |
| Capital Expenditure | 6.13B | 8.80B | 9.08B | 7.56B | 2.23B | 2.07B | 15.4B | 11.5B | 11.1B | 20.5B | 10.1B |
| Free Cash Flow | - | - | - | - | 1.55B | 9.04B | -6.25B | -1.28B | 11.5B | -628M | 2.55B |
| Ratios | |||||||||||
| ROE | 1.2% | -8.9% | -2.3% | 6.3% | -8.5% | 16.3% | 4.3% | 14.4% | 24.0% | 8.8% | 16.7% |
| ROA | 0.5% | -3.4% | -1.2% | 3.2% | -3.8% | 9.2% | 2.2% | 7.7% | 12.6% | 5.9% | 11.2% |
| Net Profit Margin | 1.0% | -6.3% | -2.2% | 5.6% | -8.7% | 16.2% | 3.8% | 12.1% | 23.8% | 10.7% | 21.1% |
| Debt to Equity | 0.98x | 1.26x | 0.70x | 0.72x | 1.01x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Meta Biomed Co. Ltd dividends
- Dividend yield
- 0.71%
- Forward dividend
- -
- Payout ratio
- 6.2%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 685M | 26 | 6.2% |
| 2024 | KRW 457M | 20 | 2.0% |
| 2023 | KRW 457M | 20 | 4.5% |
| 2022 | KRW 458M | 20 | 17.4% |
| 2021 | KRW 229M | 10.00 | 2.4% |
| 2020 | KRW 233M | 10 | - |
| 2019 | KRW 233M | 10 | 7.0% |
| 2018 | KRW 215M | 9.22 | - |
| 2017 | KRW 215M | 10 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Apr 23, 2010.
Who owns Meta Biomed Co. Ltd
- Insiders 23.75%
- Institutions 0.35%
- Public & others 75.91%
- Shares outstanding 23.5M
- Free float 17.1M
Meta Biomed Co. Ltd company profile
- Company name
- Meta Biomed Co. Ltd
- Ticker
- 059210.KQ
- ISIN
- KR7059210005
- Exchange
- KOSDAQ
- Listed since
- Apr 15, 2008
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 255
- Fiscal year end
- December
- Address
- 270 Osongsaengmyeong1-ro, Cheongju, South Korea, 281-61
- Phone
- 82 4 3218 1981
- Website
- meta-biomed.com
About Meta Biomed Co. Ltd
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone products consisting of bone graft substitutes and cement; and cosmetic medical products, as well as ultrasonic imaging diagnosis devices. The company was formerly known as Metadental Co., Ltd. and changed its name to Meta Biomed Co., Ltd. in 2001. Meta Biomed Co., Ltd. was founded in 1990 and is headquartered in Cheongju, South Korea.
Meta Biomed Co. Ltd management
2- Mr. Seok-Song OhChief Exec. Officer and Representative Director · born 1954
- Min-Ha HwangChief Exec. Officer · born 1956